MedTrace Logo

XELOX in Advanced Biliary Tract Carcinoma After Failure of Gemcitabine-based Chemotherapy

NCT02350686 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 67

Last updated 2019-05-20

No results posted yet for this study

Summary

Phase II study of second line capecitabine plus oxaliplatin (XELOX) in patients with advanced biliary tract carcinoma after failure of gemcitabine-based chemotherapy.

Conditions

  • Biliary Tract Cancer

Interventions

DRUG

capecitabine

XELOX every 3 weeks will be continued until disease progression, patients' refusal or upto 8 cycles

DRUG

oxaliplatin

XELOX every 3 weeks will be continued until disease progression, patients' refusal or upto 8 cycles

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-14
Primary Completion
2019-12-31
Completion
2020-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02350686 on ClinicalTrials.gov